Form 4: Tourmaline Bio Director Caley Castelein Granted 16,800 Stock Options

Tourmaline Bio, Inc. Director Caley Castelein was granted 16,800 stock options with an exercise price of $18.73, vesting on the earlier of June 4, 2026, or the 2026 Annual Meeting of Stockholders.

Summary

• Caley Castelein, a Director of Tourmaline Bio, Inc. (TRML), was granted 16,800 stock options.
• The options have an exercise price of $18.73 per share.
• The transaction date for this grant was June 4, 2025.
• The options will vest 100% on the earlier of June 4, 2026 (anniversary of the transaction date) or the date of the Issuer's 2026 Annual Meeting of Stockholders, contingent on continued service.
• The options expire on June 4, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive sign of continued alignment between management/board and shareholder interests, and a standard practice for incentivizing long-term commitment. It's not a major market-moving event but generally viewed favorably.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, incentivizing long-term value creation.
• The options represent a form of compensation for the director's continued service to the company.

Future Outlook

The stock options are set to vest on the earlier of June 4, 2026, or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the director's continued service. The options have an expiration date of June 4, 2035.

Industry Context

This is a routine equity compensation event for a director, common across publicly traded companies in all industries, including the biotechnology sector where Tourmaline Bio operates. It reflects standard corporate governance practices for incentivizing board members.

Comparison to Industry Standards

• The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, aligning director incentives with long-term shareholder value. The specific number of options and exercise price would typically be benchmarked against peer companies of similar market capitalization and stage of development, though this document does not provide such comparative data.

Stakeholder Impact

• Shareholders: Potential for minor dilution if options are exercised, but also benefit from incentivized director performance.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Next Steps

• Continued service of Caley Castelein as a Director of Tourmaline Bio, Inc.
• Vesting of the 16,800 stock options on the earlier of June 4, 2026, or the 2026 Annual Meeting of Stockholders.
• Potential exercise of the options by Caley Castelein before the expiration date of June 4, 2035.

Key Dates

Recommendation

Keywords

Tourmaline Bio, TRML, SEC Form 4, Stock Option, Director Compensation, Equity Grant, Caley Castelein, Beneficial Ownership